Zydus Lifesciences announced that it has got approval from the US Food and medicine Administration to offer a generic medicine used to treat specific stomach and esophageal issues. According to a statement from the medicine maker, the business...
The generics division of Novartis will be spun off soon. Sandoz expects to expand its pipeline and generate an additional $3 billion in net sales over the next five years, according to the Swiss company...
To avoid microbial contamination, pharmaceutical companies may have to switch to opaque plastic bottles for packing eye drops. According to people familiar with the situation, India's drug regulator is considering amending the drugs rules to allow...
TE Connectivity (TE), a global leader in connectors and sensors, is assisting Bangalore Medical Services Trust (BMST) operations by contributing medical equipment to strengthen its blood bank infrastructure.Vishwanath S, managing director and...
The Coalition for Epidemic Preparedness Innovations (CEPI) and aVaxziPen Ltd., a biotech company developing a novel needle-free vaccine delivery platform, have announced a partnership to advance the development of two vaccine candidates...
Telangana has embarked on enormous infrastructure development projects in order to compete worldwide and attract investments, according to state Industries and Commerce Minister K.T. Rama Rao. He mentioned the development of the Kakatiya Mega...
On Monday, premarket trading saw a sharp increase in the shares of several cancer drug companies after the companies presented encouraging clinical trial results for their treatments at a Chicago industry conference...
Danish drug developer Novo Nordisk said on Monday it had started talks to buy a controlling stake in French medical device designer Biocorp.The Danish company said it had entered into exclusive negotiations with Bio Jag, Biocorp's main shareholder,..
Eyestem Research has announced that it has submitted an Investigational New Drug (IND) application to the Central Drugs Standards Control Organisation, India (CDSCO) to begin the first in-human trials of Eyecyte-RPE for subjects with medium- to...
Dr Reddy's Laboratories Ltd announced that its DRL_TC tocilizumab biosimilar candidate met primary and secondary endpoints in a Phase I study. This Phase I study compared the pharmacokinetic equivalence, safety, and immunogenicity of Dr. Reddy's ...
, CDSCO.jpg)
.jpg)